Nanomedicine Targets CANCER: Viewing each human body as a system of interacting molecular networks and targeting disruptions in the system with nanoscale technologies can transform how disease is understood, attacked and possibly prevented

. Author manuscript; available in PMC: 2013 Jul 3.

Published in final edited form as: Sci Am. 2009 Feb;300(2):44–51. doi: 10.1038/scientificamerican0209-44

PARTICLE TYPE	DEVELOPMENT STAGE	EXAMPLES
Liposome	FDA approved	DaunoXome, Doxil
Albumin-based	FDA approved	Abraxane
Polymeric micelle	Clinical trials	Genexol-PM, SP1049C, NK911, NK012, NK105, NC-6004
Polymer-drug conjugate	Clinical trials	XYOTAX (CT-2103), CT-2106, IT-101, AP5280, AP5346, FCE28068 (PK1), FCE28069 (PK2), PNU166148, PNU166945, MAG-CPT, DE-310, Pegamotecan, NKTR-102, EZN-2208
Targeted liposome	Clinical trials	MCC-465, MBP-426, SGT-53
Targeted polymer-based particle	Clinical trials	FCE28069(PK2), CALAA-01
Solid inorganic or metal particle	Clinical trials (gold) and preclinical	Carbon nanotubes, silica particles, gold particles (CYT-6091)
Dendrimer	Preclinical	Polyamidoamine (PAMAM)